FoxO6 integrates insulin signaling with MTP for regulating VLDL production in the liver

Endocrinology

Volumn 155, Issue 4, 2014, Pages 1255-1267

  Kim, Dae Hyun ^a   Zhang, Ting ^a   Lee, Sojin ^a   Calabuig Navarro, Virtu ^a   Yamauchi, Jun ^a   Piccirillo, Ann ^a   Fan, Yong ^a   Uppala, Radha ^a   Goetzman, Eric ^a   Dong, H Henry ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FORKHEAD TRANSCRIPTION FACTOR; INSULIN; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; TRANSCRIPTION FACTOR FOXP6; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATALYSIS; CELL STRAIN HEPG2; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA BINDING; FAST PROTEIN LIQUID CHROMATOGRAPHY; FAT TOLERANCE TEST; GENE MUTATION; HUMAN; HUMAN CELL; HYPERTRIGLYCERIDEMIA; IMMUNOBLOTTING; IMMUNOPRECIPITATION; INSULIN RELEASE; INSULIN RESISTANCE; LIPID LIVER LEVEL; LIVER CELL; LIVER METABOLISM; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION;

ANIMALS; CARRIER PROTEINS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION; HEP G2 CELLS; HEPATOCYTES; HUMANS; HYPERTRIGLYCERIDEMIA; INSULIN; LIPIDS; LIPOPROTEIN LIPASE; LIPOPROTEINS, VLDL; LIVER; MALE; MICE; MICE, TRANSGENIC; PHOSPHORYLATION; PPAR GAMMA; PROMOTER REGIONS, GENETIC; SIGNAL TRANSDUCTION; TRIGLYCERIDES;

EID: 84897869621     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1856     Document Type: Article

References (54)

1. Choi SH, Ginsberg HN. Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance. Trends Endocrinol Metab. 2011;22:353-363.
2. Betteridge DJ. Diabetic dyslipidaemia. Diabetes Obes Metab. 2000;2 (Suppl 1):S31-S36. (Pubitemid 33072171)
3. Marcoux C, Tremblay M, Fredenrich A, Davignon J, Cohn JS. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins. Metabolism. 2001;50:112-119. (Pubitemid 32058558)
4. Knopp RH, Retzlaff B, Aikawa K, Kahn SE. Management of patients with diabetic hyperlipidemia. Am J Cardiol. 2003;91:24E-28E. (Pubitemid 36385072)
5. Stewart MW, Laker MF, Alberti KG. The contribution of lipids to coronary heart disease in diabetes mellitus. J Intern Med Suppl. 1994;736:41-46.
6. DeFronzo RA. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerosis. Neth J Med. 1997;50:191-197. (Pubitemid 27240251)
7. Krauss RM. Atherogenicity of triglyceride-rich lipoproteins. Am J Cardiol. 1998;81(4A):13B-17B (Pubitemid 28113940)
8. Brewer HB Jr. Hypertriglyceridemia: changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease. Am J Cardiol. 1999;83(9B):3F-12F
9. Bard JM, Charles MA, Juhan-Vague I, et al. Accumulation of triglyceride-rich lipoprotein in subjects with abdominal obesity. Arterioscher Thromb Vasc Biol. 2001;21:407-414.
10. Olivieri O, Stranieri C, Bassi A, et al. ApoC-III gene polymorphisms and risk of coronary artery disease. J Lipid Res. 2002;43:1450-1457.
11. Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev. 2002;23:201-229. (Pubitemid 34299024)
12. Chan DC, Watts GF, Barrett PH, Mamo JC, Redgrave TG. Markers of triglyceride-rich lipoprotein remnant metabolism in visceral obesity. Clin Chem. 2002;48:278-283. (Pubitemid 34107264)
13. Nieves DJ, Cnop M, Retzlaff B, et al. The atherogenic lipoprotein profile associated with obesity and insulin resistance is largely attributable to intra-abdominal fat. Diabetes. 2003;52:172-179. (Pubitemid 36042123)
14. Ota T, Gayet C, Ginsberg HN. Inhibition of apolipoprotein B100 secretion by lipid-induced hepatic endoplasmic reticulum stress in rodents. J Clin Invest. 2008;118:316-332.
15. Kamagate A, Dong HH. FoxO1 integrates insulin signaling to VLDL production. Cell Cycle. 2008;7:3162-3170.
16. Accili D, Arden KC. FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell. 2004;117:421-426. (Pubitemid 38610228)
17. Hwangbo DS, Gershman B, Gersham B, Tu MP, Palmer M, Tatar M. Drosophila dFOXO controls lifespan and regulates insulin signalling in brain and fat body. Nature. 2004;429:562-566. (Pubitemid 38737660)
18. Lee SS, Kennedy S, Tolonen AC, Ruvkun G. DAF-16 target genes that control C. elegans life-span and metabolism. Science. 2003;300:644-647. (Pubitemid 36520589)
19. Kim DH, Zhang T, Lee S, Dong HH. 2013 FoxO6 in glucose metabolism. J Diabetes. 2013;5:233-240
20. Kim DH, Perdomo G, Zhang T, et al. FoxO6 integrates insulin signaling with gluconeogenesis in the liver. Diabetes. 2011;60:2763-2774.
21. Jacobs FM, van der Heide LP, Wijchers PJ, Burbach JP, Hoekman MF, Smidt MP. FoxO6, a novel member of the FoxO class of transcription factors with distinct shuttling dynamics. J Biol Chem. 2003;278:35959-35967. (Pubitemid 37139914)
22. van der Heide LP, Jacobs FM, Burbach JP, Hoekman MF, Smidt MP. FoxO6 transcriptional activity is regulated by Thr26 and Ser184, independent of nucleo-cytoplasmic shuttling. Biochem J. 2005;391:623-629. (Pubitemid 41634788)
23. Kamagate A, Qu S, Perdomo G, et al. FoxO1 mediates insulin-dependent regulation of hepatic VLDL production in mice. J Clin Invest. 2008;118:2347-2364. (Pubitemid 351872351)
24. Altomonte J, Cong L, Harbaran S, et al. Foxo1 mediates insulin action on ApoC-III and triglyceride metabolism. J Clin Invest. 2004;114:1493-1503. (Pubitemid 40385579)
25. Kamagate A, Kim DH, Zhang T, et al. FoxO1 links hepatic insulin action to endoplasmic reticulum stress. Endocrinology. 2010;151:3521-3535.
26. Su D, Coudriet GM, Hyun Kim D, et al. FoxO1 links insulin resistance to proinflammatory cytokine IL-1β production in macrophages. Diabetes. 2009;58:2624-2633.
27. Qu S, Perdomo G, Su D, D'Souza FM, Shachter NS, Dong HH. Effects of apoA-V on HDL and VLDL metabolism in APOC3 transgenic mice. J Lipid Res. 2007;48:1476-1487. (Pubitemid 47312010)
28. Qu S, Altomonte J, Perdomo G, et al. Aberrant forkhead box O1 function is associated with impaired hepatic metabolism. Endocrinology. 2006;147:5641-5652. (Pubitemid 44833481)
29. Jansen H, Breedveld B, Schoonderwoerd K. Role of lipoprotein lipases in postprandial lipid metabolism. Atherosclerosis. 1998;141(Suppl 1):S31-S34.
30. Chatterjee C, Sparks DL. Hepatic lipase, high density lipoproteins, and hypertriglyceridemia. Am J Pathol. 2011;178:1429-1433.
31. Fan Y, Menon RK, Cohen P, et al. Liver-specific deletion of the growth hormone receptor reveals essential role of growth hormone signaling in hepatic lipid metabolism. J Biol Chem. 2009;284:19937-19944.
32. Raabe M, Véniant MM, Sullivan MA, et al. Analysis of the role of microsomal triglyceride transfer protein in the liver of tissue-specific knockout mice. J Clin Invest. 1999;103:1287-1298. (Pubitemid 29218299)
33. Hussain MM, Nijstad N, Franceschini L. Regulation of microsomal triglyceride transfer protein. Clin Lipidol. 2011;6:293-303.
34. Adeli K, Taghibiglou C, Van Iderstine SC, Lewis GF. Mechanisms of hepatic very low-density lipoprotein overproduction in insulin resistance. Trends Cardiovasc Med. 2001;11:170-176. (Pubitemid 32946865)
35. Morán-Salvador E, López-Parra M, García-Alonso V, et al. Role for PPARγ in obesity-induced hepatic steatosis as determined by hepatocyte-and macrophage-specific conditional knockouts. FASEB J. 2011;25:2538-2550.
36. Schadinger SE, Bucher NL, Schreiber BM, Farmer SR. PPARγ2 regulates lipogenesis and lipid accumulation in steatotic hepatocytes. Am J Physiol Endocrinol Metab. 2005;288:E1195-E1205. (Pubitemid 40726807)
37. Zhang YL, Hernandez-Ono A, Siri P, et al. Aberrant hepatic expression of PPARγ2 stimulates hepatic lipogenesis in a mouse model of obesity, insulin resistance, dyslipidemia, and hepatic steatosis. J Biol Chem. 2006;281:37603-37615. (Pubitemid 46042063)
38. Matsumoto M, Han S, Kitamura T, Accili D. Dual role of transcription factor FoxO1 in controlling hepatic insulin sensitivity and lipid metabolism. J Clin Invest. 2006;116:2464-2472. (Pubitemid 44330145)
39. Bernal-Mizrachi E, Wen W, Stahlhut S, Welling CM, Permutt MA. Islet β cell expression of constitutively active Akt1/PKB α induces striking hypertrophy, hyperplasia, and hyperinsulinemia. J Clin Invest. 2001;108:1631-1638. (Pubitemid 33144873)
40. Ginsberg HN, Fisher EA. The ever-expanding role of degradation in the regulation of apolipoprotein B metabolism. J Lipid Res. 2009;50(Suppl):S162-166.
41. Gavrilova O, Haluzik M, Matsusue K, et al. Liver peroxisome proliferator-activated receptor γ contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem. 2003;278:34268-34276. (Pubitemid 37553270)
42. Matsusue K, Haluzik M, Lambert G, et al. Liver-specific disruption of PPARγ in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J Clin Invest. 2003;111:737-747. (Pubitemid 36278592)
43. Zhou J, Febbraio M, Wada T, et al. Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARγ in promoting steatosis. Gastroenterology. 2008;134:556-567.
44. Bedoucha M, Atzpodien E, Boelsterli UA. Diabetic KKAy mice exhibit increased hepatic PPARγ1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones. J Hepatol. 2001;35:17-23. (Pubitemid 32646220)
45. Memon RA, Tecott LH, Nonogaki K, et al. Up-regulation of peroxisome proliferator-activated receptors (PPAR-α) and PPAR-γ messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-γ-responsive adipose tissue-specific genes in the liver of obese diabetic mice. Endocrinology. 2000;141:4021-4031.
46. Rahimian R, Masih-Khan E, Lo M, van Breemen C, McManus BM, Dube GP. Hepatic over-expression of peroxisome proliferator activated receptor γ2 in the ob/ob mouse model of non-insulin dependent diabetes mellitus. Mol Cell Biochem. 2001;224:29-37. (Pubitemid 32962649)
47. Inoue M, Ohtake T, Motomura W, et al. Increased expression of PPARγ in high fat diet-induced liver steatosis in mice. Biochem Biophys Res Commun. 2005;336:215-222. (Pubitemid 41253423)
48. Pettinelli P, Videla LA. Up-regulation of PPAR-γ mRNA expression in the liver of obese patients: an additional reinforcing lipogenic mechanism to SREBP-1c induction. J Clin Endocrinol Metab. 2011;96:1424-1430.
49. Sparks JD, Sparks CE, Adeli K. Selective hepatic insulin resistance, VLDL overproduction, and hypertriglyceridemia. Arterioscler Thromb Vasc Biol. 2012;32:2104-2112.
50. Sparks JD, Dong HH. FoxO1 and hepatic lipid metabolism. Curr Opin Lipidol. 2009;20:217-226.
51. Risser TR. Intestinal very low density lipoprotein secretion in insulin-deficient rats. Diabetes. 1978;27:902-908. (Pubitemid 9023046)
52. Haidari M, Leung N, Mahbub F, et al. Fasting and postprandial overproduction of intestinally derived lipoproteins in an animal model of insulin resistance. Evidence that chronic fructose feeding in the hamster is accompanied by enhanced intestinal de novo lipogenesis and ApoB48-containing lipoprotein overproduction. J Biol Chem. 2002;277:31646-31655. (Pubitemid 34968968)
53. Avramoglu RK, Qiu W, Adeli K. Mechanisms of metabolic dyslipidemia in insulin resistant states: deregulation of hepatic and intestinal lipoprotein secretion. Front Biosci. 2003;8:d464-476. (Pubitemid 38943204)
54. Lewis GF, Uffelman K, Naples M, Szeto L, Haidari M, Adeli K. Intestinal lipoprotein overproduction, a newly recognized component of insulin resistance, is ameliorated by the insulin sensitizer rosiglitazone: studies in the fructose-fed Syrian golden hamster. Endocrinology. 2005;146:247-255. (Pubitemid 40051746)